52-Week Efficacy and Safety Results from SPIRIT-P1: A Phase 3 Study of Ixekizumab in Patients with Active Psoriatic Arthritis

被引：0
|
作者：
Mease, Philip [1 ,2 ]
Okada, Masan [3 ]
Kishimoto, Mitsumasa [4 ]
Shuler, Catherine [5 ]
Carlier, Hilde [5 ]
Lin, Chen-Yen [5 ]
Mou, Jiani [5 ]
Moriarty, Susan [5 ]
Lee, Chin [5 ]
Gladman, Dafna [6 ]
机构：
[1] Swedish Med Ctr, Seattle, WA USA
[2] Univ Washington, Sch Med, Seattle, WA USA
[3] St Lukes Int Hosp, Tokyo, Japan
[4] St Lukes Int Hosp, Tokyo, Japan
[5] Eli Lilly & Co, Indianapolis, IN 46285 USA
[6] Univ Toronto, Toronto, ON, Canada
来源：
JOURNAL OF RHEUMATOLOGY | 2017年 / 44卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
176
引用
收藏
页码：925 / 925
页数：1
相关论文
共 50 条
  • [21] EFFICACY OF IXEKIZUMAB IMPROVING SF-36 SCORES IN BIOLOGIC DMARD-NAIVE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 3 STUDY (SPIRIT-P1)
    Strand, V.
    Gottlieb, A. B.
    Kvien, T. K.
    Naegeli, A.
    Lin, C-Y.
    Benichou, O.
    Birt, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2017, 76 : 1334 - 1335
  • [22] EFFICACY AND SAFETY OF RISANKIZUMAB (RZB) FOR ACTIVE PSORIATIC ARTHRITIS (PSA): 52-WEEK RESULTS FROM KEEPSAKE 1
    Kristensen, L. E.
    Keiserman, M.
    Papp, K.
    Mccasland, L.
    White, D.
    Lu, W.
    Soliman, A. M.
    Eldred, A.
    Barcomb, L.
    Behrens, F.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 823 - 824
  • [23] Efficacy and Safety of Ixekizumab with or Without Methotrexate in Biologic-Naïve Patients with Psoriatic Arthritis: 52-Week Results from SPIRIT-H2H Study
    Josef S. Smolen
    Anthony Sebba
    Eric M. Ruderman
    Hendrik Schulze-Koops
    Christophe Sapin
    Amanda M. Gellett
    Aubrey Trevelin Sprabery
    Lingnan Li
    Inmaculada de la Torre
    Gaia Gallo
    Soyi Liu-Leage
    Sreekumar Pillai
    Paulo Reis
    Peter Nash
    Rheumatology and Therapy, 2020, 7 : 1021 - 1035
  • [24] Safety Profiles of Ixekizumab versus Adalimumab: 52-Week Results from a Head-to-Head Comparison in Patients With Active Psoriatic Arthritis
    Mease, Philip
    Smolen, Josef
    Kavanaugh, Arthur
    Nash, Peter
    Gallo, Gaia
    Liu-Leage, Soyi
    Sapin, Christophe
    Genovese, Mark
    Bessette, Louis
    JOURNAL OF RHEUMATOLOGY, 2021, 48 (07) : 1167 - 1167
  • [25] SAFETY PROFILES OF IXEKIZUMAB VERSUS ADALIMUMAB: 52-WEEK RESULTS FROM A HEAD-TO-HEAD COMPARISON IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS
    Mease, P. J.
    Smolen, J. S.
    Kavanaugh, A.
    Nash, P.
    Gallo, G.
    Leage, S. Liu
    Sapin, C.
    Genovese, M. C.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1698 - 1698
  • [26] Safety Profiles of Ixekizumab versus Adalimumab: 52-Week Results from a Head-to-Head Comparison in Patients with Active Psoriatic Arthritis
    Mease, Philip
    Smolen, Josef
    Kavanaugh, Arthur
    Nash, Peter
    Gallo, Gaia
    Liu-Leage, Soyi
    Sapin, Christophe
    Genovese, Mark
    ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [27] Efficacy and Safety of Bimekizumab in Patients With Psoriatic Arthritis With or Without Methotrexate: 52-Week Results From Two Phase 3 Studies
    McInnes, Iain B.
    Mease, Philip J.
    Tanaka, Yoshiya
    Gossec, Laure
    Husni, M. Elaine
    Kristensen, Lars Erik
    Warren, Richard B.
    Ink, Barbara
    Bajracharya, Rajan
    Coarse, Jason
    Gottlieb, Alice B.
    ACR OPEN RHEUMATOLOGY, 2024, 6 (11) : 720 - 731
  • [28] Ixekizumab vs. adalimumab for the treatment of psoriatic arthritis: 52-week efficacy and safety outcomes
    Edwards, C. J.
    Bradley, A.
    Nassab, M. H.
    Moller, B.
    Machold, K. P.
    Sapin, C.
    Ranza, R.
    Liu-Leage, S.
    SWISS MEDICAL WEEKLY, 2020, : 7S - 7S
  • [29] IXEKIZUMAB VS. ADALIMUMAB FOR THE TREATMENT OF PSORIATIC ARTHRITIS: 52-WEEK EFFICACY AND SAFETY OUTCOMES
    Chaudhury, Koyel
    Bradley, Andrew
    Nassab, Mani Haschemi
    Moeller, Burkhard
    Machold, Klaus P.
    Sapin, Christophe
    Ranza, Roberto
    Leage, Soyi Liu
    Nash, Peter
    INTERNAL MEDICINE JOURNAL, 2021, 51 : 33 - 34
  • [30] Ixekizumab treatment of biologic-naive patients with active psoriatic arthritis: 3-year results from a phase III clinical trial (SPIRIT-P1)
    Chandran, Vinod
    van der Heijde, Desiree
    Fleischmann, Roy M.
    Lespessailles, Eric
    Helliwell, Philip S.
    Kameda, Hideto
    Burgos-Vargas, Ruben
    Erickson, Janelle S.
    Rathmann, Suchitrita S.
    Sprabery, Aubrey Trevelin
    Birt, Julie A.
    Shuler, Catherine L.
    Gallo, Gaia
    RHEUMATOLOGY, 2020, 59 (10) : 2774 - 2784
12345